Biostream's Innovative Urine Test Receives FDA Breakthrough Designation for iNPH Diagnosis

Biostream's Breakthrough in Neurological Diagnostics



Biostream, a pioneering company focused on developing urine-based diagnostics for neurological conditions, has made significant strides in the medical field. They recently announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Device Designation to their innovative urine test designed to aid in diagnosing idiopathic normal pressure hydrocephalus (iNPH). This designation was officially granted on November 12, 2026, and highlights the test's potential to revolutionize the way healthcare providers identify this often-misdiagnosed condition.

Understanding Normal Pressure Hydrocephalus


Normal pressure hydrocephalus is characterized by an abnormal buildup of cerebrospinal fluid in the brain. This condition typically manifests in patients aged 60 and older, leading to a range of symptoms, including walk difficulties, cognitive impairments, and urinary control issues. Unfortunately, iNPH is frequently misidentified as Alzheimer's disease or other neurodegenerative disorders, causing delays in treatment and worsening patient outcomes.

Dr. Meital Segev Bar, Co-founder and CEO of Biostream, expressed the urgency behind their innovation by highlighting a common scenario where individuals suffering from iNPH are misdiagnosed, contributing to a lack of effective treatment. "Too many people with normal pressure hydrocephalus are told their symptoms are Alzheimer's or simply old age... when a treatable condition is behind them," she stated. This urgent need has driven Biostream's mission to develop a more accessible and non-invasive diagnostic solution.

The Innovative Urine Test


The Biostream test distinguishes itself by measuring specific proteins in a urine sample, which are crucial indicators of iNPH. By utilizing a proprietary algorithm, the test generates a probability score that assists healthcare professionals in evaluating whether a patient might have iNPH. This advancement enables clinicians to apply objective biomarkers—making the decision-making process more scientifically grounded.

Unlike traditional diagnostic methods, which often include brain imaging and invasive spinal fluid tests, Biostream's urine test provides a non-invasive alternative that can be more readily implemented in various healthcare settings. The FDA’s Breakthrough Device Designation not only recognizes the test's potential but also means that Biostream will receive prioritized review and support from the FDA during its development stages.

Importance of Early Diagnosis


Research has shown that diagnosing iNPH early can lead to significant improvements through available treatments, such as shunt surgeries that help alleviate the buildup of excess cerebrospinal fluid. However, due to its symptoms resembling other forms of dementia, many patients go unrecognized or misdiagnosed. Recent estimates suggest that iNPH affects approximately 2-4% of individuals aged 65 and over, with reports indicating that upwards of 80% of these patients remain untreated. Biostream's urine test could dramatically change this landscape by facilitating earlier recognition and treatment, potentially enhancing the quality of life for many.

Future Developments


Looking ahead, Biostream plans to conduct a prospective clinical validation study across U.S. academic medical centers in 2027 to further establish the test's efficacy. As the company continues to innovate in the field of neurological care, it remains committed to providing healthcare professionals with the tools necessary to diagnose and manage neurological disorders more effectively.

Conclusion


Biostream’s innovative urine-based biomarker test represents a crucial step toward enhancing the diagnosis and treatment of normal pressure hydrocephalus. By bridging the gap between traditional diagnostic methods and the need for more accessible testing options, Biostream may very well be on the verge of changing the standard of care for patients suffering from this condition. As we look toward the future, the collaborative effort between Biostream and the FDA promises to expedite the development of this vital diagnostic tool, ultimately benefiting countless patients in need of timely and accurate diagnoses.

Topics Health)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.